MOSCOW, February 2./TASS/. Russia’s Sputnik V vaccine against coronavirus has proved almost equally effective across different age groups, the head of the Gamaleya Research Center for Epidemiology and Microbiology, Alexander Gintsburg, said on Tuesday.
"One of the main achievements demonstrated in phase 3 [trial] is that the vaccine showed almost equal epidemiological efficiency among all groups," the head of the center that had developed the vaccine, told a news conference.
Earlier, The Lancet, one of the world's oldest and most respected medical journals, published interim results of a phase 3 trial of Sputnik V, confirming that the vaccine candidate "appears safe and effective." Sputnik V, which is based on a well-studied human adenoviral vectors platform, is the world’s first registered vaccine against the coronavirus. Russia’s Sputnik V vaccine against COVID-19 showed strong efficacy during a phase 3 clinical trial: 91.6%, the Russian Direct Investment Fund (RDIF) said in a press release on Tuesday. The efficacy in the age group of over 60 was 91.8%, RDIF added.
RDIF also noted that 98% of volunteers had developed antibodies.
The Sputnik V coronavirus vaccine’s effectiveness in terms of developing a cell-mediated immunity is 100%. "The level of virus neutralizing antibodies of volunteers vaccinated with Sputnik V is 1.3-1.5 times higher than the level of antibodies of patients who recovered from COVID-19," RDIF said.